**Safety of paclitaxel drug coated balloon only angioplasty in STEMI**

**Short title: Safety of DCB angioplasty in STEMI**

Ioannis Merinopoulosa,b MD, MSc, MRCP, Tharusha Gunawardenaa,b MD, BSc, MRCP, Natasha Corballisa,b MD, MRCP, U Bhalraama,b BSc, MD, Johannes Reinholda,b MD, PhD, MRCP, Upul Wickramarachchia,b MD, MRCP, Clint Maarta MD, MRCP, Tim Gilberta MD, FRCP, Paul Richardsona BSc, Sreekumar Sulfia MD, MRCP Toomas Sareva MD, FRCP, Chris Sawha MD, MRCP, Trevor Wistowa MD, MRCP, Alisdair Rydinga MD, PhD, FRCP, Mohamed O Mohamedc,d MD, PhD, MRCP, Aris Perperogloue PhD, Mamas A Mamasc MD, DPhil, Vassilios S Vassilioua,b, # MD, PhD, FESC, FRCP, FACC, Simon C Eccleshalla, # MD, MRCP

a Department of Cardiology, Norfolk and Norwich University Hospital, UK; b Norwich Medical School, University of East Anglia, UK; c Keele Cardiovascular Research Group, Keele University, Staffordshire, UK; d Institute of Health Informatics, University College London, UK, e Department of Mathematics, University of Newcastle, UK

# VSV and SCE contributed equally

Address for correspondence

Professor Vassilios S Vassiliou

2.06 Bob Champion Research & Education Building

Norwich Medical School, University of East Anglia

Norwich, NR4 7TJ

Email: [v.vassiliou@uea.ac.uk](mailto:v.vassiliou@uea.ac.uk), Telephone: +44 (0)1603 59 2534

Word count: 4575

**Funding:** This is an investigator-initiated study partially supported by the National Institute for Health Research Capability Fund from Norfolk and Norwich University Hospital and B Braun Ltd. Dr Corballis was an NIHR Academic Clinical Fellow. JR received funding as an NIHR Clinical Lecturer.

**Conflicts of interest / competing interests:**

VSV received honoraria for speaking at conferences by Daichii-Sankyo and Novartis and a research grant from B Braun for investigator-initiated research.

SCE received research grants for investigator-initiated research and lecture honoraria from B Braun. He also acts as a consultant for B Braun, Medtronic and MedAlliance.

The other authors have nothing to declare.

**Abstract**

Background: Primary percutaneous coronary intervention (pPCI) with drug eluting stents (DES) has emerged as the standard of care, but stent related events have persisted. Drug coated balloon (DCB)-only angioplasty is an emerging technology, although not fully evaluated compared with DES in context of pPCI. We aimed to investigate the safety of DCB-only angioplasty compared to 2nd generation DES in pPCI.

Methods: We compared all-cause mortality and net adverse cardiac events (cardiovascular mortality, acute coronary syndrome, ischaemic stroke or transient ischaemic attack, major bleeding and unplanned target lesion revascularisation (TLR)) of all patients treated with DCB-only or 2nd generation DES-only for first presentation of STEMI due to de novo disease between 1st January 2016 and 15th November 2019. Patients treated with both DCB and DES were excluded. Data were analysed with Cox regression models, Kaplan Meier estimator plots and propensity score matching.

Results: Among 1139 patients with STEMI due to de novo disease; 452 were treated with DCB and 687 were treated with DES. After a median follow up of >3 years, the all-cause mortality was 49/452 and 62/687 in the DCB and DES group respectively (p=0.18). On multivariable Cox regression analysis, there was no difference in mortality between DCB and DES, in the full and propensity score-matched cohorts. Age, frailty risk, history of heart failure and family history of ischaemic heart disease remained significant independent predictors of mortality. There was no difference in any of the secondary endpoints including unplanned TLR.

Conclusion: DCB-only angioplasty appears safe when compared to DES for STEMI, in terms of all-cause mortality and all net adverse cardiac events including unplanned TLR. DCB may be an efficacious and safe alternative to DES in selected patient groups.

Registration

<https://clinicaltrials.gov/ct2/show/NCT04482972> Unique identifier: NCT04482972

**Condensed abstract**

There are limited data about the safety of DCB-only angioplasty in STEMI and how it compares with 2nd generation DES. In this study, we report 1139 patients treated in our institution; 452 with DCB and 687 with DES for STEMI due to de novo disease between 1st January 2016 and 15th November 2019. We obtained patient outcomes from the Hospital Episodes Statistics of NHS digital. There was no difference in all-cause mortality or any of net adverse cardiac events including unplanned TLR after a median >3 years. The results remained unchanged after propensity score matched analysis. In conclusion DCB-only angioplasty for STEMI appears safe and may be considered in selected patients.

**Abbreviations**

ACS: Acute Coronary Syndrome

CABG: Coronary Artery Bypass Graft

DCB: Drug Coated Balloon

DES: Drug Eluting Stent

TIA: Transient Ischaemic Attack

TLR: Target Lesion Revascularisation



**Introduction**

Primary percutaneous coronary intervention (pPCI) is the guideline recommended treatment strategy for patients with ST Elevation Myocardial Infarction (STEMI), with studies demonstrating improved patient outcomes including mortality compared to thrombolysis (1). Stents were initially developed to treat acute complications of balloon angioplasty, such as flow limiting dissections and acute vessel recoil. Since then, implantation of a drug eluting stent (DES) has emerged as the standard of care (1). Despite great advances in stent technology over the years and evolution of 2nd generation DES with significantly better patient outcomes and reduced stent-related events (2), stent-related complications such as stent thrombosis and in-stent restenosis have persisted. This in turn has stimulated the concept of ‘leaving nothing behind’ PCI (3). Drug coated balloons (DCB) combine the benefits of local drug delivery without the complications of a permanent stent implantation in cases where stenting was not mandated following the initial balloon angioplasty (4).

The safety and efficacy of DCB-only angioplasty has already been demonstrated in in-stent restenosis, small vessel disease and high-bleeding risk cohorts with emerging data in large vessels as well (5) (6) (7) (8) (9) (10). However, only a few, predominantly small studies have evaluated the safety of DCB-only angioplasty in the setting of pPCI (7) (11) (12) (13). The present study sought to assess the safety of DCB-only angioplasty in pPCI as compared with newer generation DES.

**Methods**

The safety of paclitaxel drug coated balloon only angioplasty for ST elevation myocardial infarction was an investigator-initiated, single centre, retrospective, propensity matched, cohort study. In our institution, patients undergoing PCI are prospectively entered in a dedicated clinical database. The study received approval from the Northwest Haydock (17/NW/0278), UK research ethics committee and Institutional Board approval by the Norfolk and Norwich University Hospital. The confidentiality advisory group waived the need for patient consent due to the retrospective nature of our study (17/CAG/0145). In our institution, usage of DCB has steadily increased and usage of second-generation DES has steadily decreased over the last ten years as shown in **Supplementary Figure 1**. From 2016 onwards more than 100 patients per year with first presentation of STEMI and de novo disease were treated with DCB-only angioplasty, representing at least 35% of all the STEMI patients. Hence, for the purposes of this study we considered patients from 2016 onwards, so that the two groups were more balanced in terms of frequency and follow up. We excluded patients with cardiac arrest, intubation or cardiogenic shock as their outcomes are determined mainly by the severity of the clinical presentation rather than the treatment strategy (Fig 1). Clinical and angiographic data were obtained from our prospectively collated database supplemented with data from electronic hospital records as required. An operator (NC) blinded to the outcomes reviewed all angiograms to confirm accuracy of treatment strategy, classify bifurcation disease, TIMI flow before and after PCI as well as coronary artery dissection post DCB implantation. A lesion was defined as bifurcation if there was a side branch more than 2mm in diameter within 5mm of the lesion. Medina subtypes 1.1.1, 1.0.1 and 0.1.1 were considered as true bifurcations. The vessel diameter was considered as the largest pre/post-dilatation balloon, DCB or DES used and lesion length was based on the DCB or DES length. Calcification was assessed by angiographic visualisation.

The primary endpoint was all-cause mortality. The secondary endpoints were cardiovascular mortality, acute coronary syndrome (ACS), stroke or transient ischaemic attack, major bleeding and target lesion revascularisation. Patient outcomes were obtained from the Hospital Episodes Statistics from NHS digital. Hospital Episode Statistics is a data warehouse containing details of all admissions, outpatient appointments and accident & emergency attendances at NHS hospitals in England. Supplementary table 1 demonstrates the ICD-10 diagnostic codes used to identify patients’ outcomes. We obtained mortality data for all patients from NHS digital. All deaths were classified as cardiovascular or non-cardiovascular by three blinded adjudicators according to academic research consortium 2 consensus (14). We used the validated Hospital Frailty Risk Score based on ICD-10 diagnostic codes to calculate the patients’ frailty index (15). We estimated the well validated ‘acuity’ score based on gender, age, serum creatinine, white blood cell count, anaemia, clinical presentation and antithrombotic medications (16). Unplanned TLR was identified following review of all patients’ angiograms who had repeat PCIs.

Statistical analysis was undertaken by an independent statistician in program R (version 3.6.0). Nominal variables are reported as counts (percentages) and compared by the Pearson’s Chi-squared test. Kolmogorov and Shapiro tests were used to assess normal distribution of continuous variables. Continuous variables not normally distributed are reported as median (interquartile range (IQR)). Wilcoxon rank sum test or Fisher’s exact test were used to compare variables as appropriate. Univariable Cox regression analyses were performed to identify predictors of mortality. Predictors with p-value <0.05 were introduced into the multivariable Cox regression model. A p-value <0.05 was considered significant. Kaplan Meier estimator curve and the log-rank test were used to plot and compare survival. Propensity score matched analysis was undertaken matching on the following variables that were significant in univariable Cox regression analysis.

**Results**

A total of 452 consecutive patients treated with paclitaxel DCB only and 687 consecutive patients treated with 2nd generation DES only were identified (Fig 1). There were 24 patients who required bailout stenting (21 for worsening dissection and 3 for worsening acute vessel recoil following DCB). These patients have not been included in the analysis as they were identified during the index procedure and received a DES – hence excluded. The mean age was 66 (±13) and 66 (±11) years old for the DCB and DES groups, respectively. Male patients accounted for 73% and 74% for the DCB and DES groups, respectively. The groups were well balanced in baseline patient characteristics as shown in table 1. There were very few differences; the DCB group had more patients with previous stroke and higher frailty index while the DES group had more patients with history of smoking.

Table 2 shows the angiographic characteristics of the target vessels treated. Overall, the groups were well balanced with very few differences. The DCB group had significantly more patients with bifurcation and true bifurcation disease treated. The DES group had a significantly larger median vessel diameter but both groups had median vessel diameter more than 3 mm.

The median follow-up for the DCB group was 34.7 months (interquartile range: 24.0 - 49.9) while for the DES group it was 41.2 months (IQR: 28.0 – 51.6) (p<0.001). The mortality rate was 49/452 (10.8%) in the DCB group and 62/687 (9%) in the DES group (hazard ratio (HR)=0.77; CI: 0.53-1.12; p=0.18). Kaplan Meier estimator plot showed that there was no significant difference in all-cause mortality associated with paclitaxel DCB compared to DES (Fig 2). Furthermore, there were no significant differences in any of the secondary endpoints, cardiovascular mortality, ACS, stroke, major bleeding or unplanned TLR (**Supplementary Figure 2**). The median length of hospitalisation post-pPCI was 2.22 days (IQR: 1.63, 2.87) for the DCB group and 2.19 days (IQR: 1.57, 2.69) for the DES group. There were six in-hospital deaths (1.3%) in the DCB group and five in the DES group (0.7%). The difference was not statistically significant (p=0.56). There were no planned or unplanned in-hospital TLR in the DCB group, while there were five unplanned in-hospital TLR in the DES group. Three patients had acute stent thrombosis while another two patients had ongoing chest pain requiring stent optimisation. Furthermore, there was no difference in all-cause mortality or unplanned TLR within 30 days. The 30-day mortality was 2% vs 1.5% (p=0.49) while the 30-day unplanned TLR was 0.2% vs 0.7% (p=0.41) for the DCB and DES group respectively. Analysis of net adverse cardiac events at the short term after propensity score matching, did not show any significant differences between DCB and DES at 30 days or 1 year.

Univariable Cox regression analysis (table 3) identified the following adverse prognostic factors for all-cause mortality: increasing age, hypertension, peripheral vascular disease, stroke, previous myocardial infarction, coronary artery bypass graft (CABG), heart failure, atrial fibrillation (AF), chronic obstructive pulmonary disease (COPD), diabetes, decreasing estimated glomerular filtration rate (eGFR), frailty, vessel treated and true bifurcation. On multivariable Cox regression analysis (table 4), only age, history of heart failure, frailty and family history of IHD remained independent predictors of mortality.

Propensity score matched analysis for all positive variables in univariable Cox regression analysis demonstrated no difference in mortality between DCB and DES (Fig 3). There were no significant differences in any of the net adverse cardiac events including unplanned TLR (supplementary figure 3). Multivariable Cox regression analysis for the propensity matched population identified frailty score, acuity score, history of heart failure and family history of IHD as independent predictors of mortality (Table 5).

Subgroup analysis according to vessel size (more or less than 3mm) or bifurcation disease demonstrated that the results were consistent in these subgroups.

**Discussion**

This is the largest cohort analysis assessing the safety of DCB-only angioplasty compared with 2nd generation DES for pPCI showing no difference in all-cause mortality between DCB and DES for STEMI and no difference in the propensity score-matched analysis. Furthermore, there was no difference in any of the net adverse cardiac events including unplanned TLR.

pPCI has significantly improved the outcomes including survival of patients presenting with STEMI (17) (18). Even though pPCI with 2nd generation DES has emerged as the standard of care, stent related events have persisted despite great advances in stent technology (8) (19) (20). DCB-only angioplasty, an emerging treatment strategy providing local drug delivery to prevent restenosis without the placement of a permanent stent, has not been fully evaluated compared to 2nd generation DES. The recent REVELATION trial demonstrated safety and efficacy of DCB compared to DES for STEMI in terms of fractional flow reserve (21). In addition, there are only few, small studies that have assessed safety of DCB compared to 2nd generation DES, demonstrating that DCB-only strategy is feasible in STEMI (12) (13) (22). This is the largest analysis reporting on the most relevant, hard endpoint of all-cause mortality and also all net adverse cardiac events including unplanned TLR.

We have demonstrated that DCB-only angioplasty is safe in patients with STEMI and de novo disease compared to 2nd generation DES. In our institution, over the last six years a comparable number of patients with first presentation of STEMI due to de novo coronary artery disease were treated with DCB-only strategy and DES-only strategy, while at the same time, the number of patients treated with both DCB and DES remained low. In the short term, DCB-only angioplasty appears safe with no difference in in-hospital outcomes and reassuringly no cases of acute vessel closure. Furthermore, there was no difference in mortality or any of the net adverse cardiac events including unplanned TLR, after >3 years (median) follow up. These results were similar following propensity score matched analysis and consistent with previous smaller studies (12) (13) (22). Subgroup analysis demonstrated consistent results in both small or large vessels and in bifurcation disease. Further studies will need to verify these results in such subgroups. Given the equipoise of our results, it is important to note that in the context of STEMI, a DCB-only strategy may provide an advantage in cases of a) uncertain vessel size resulting in inadequate stent apposition b) uncertainty about antiplatelet compliance or bleeding risk and c) may simplify treatment of complex bifurcation lesions (5).

We included a large number of consecutive patients with STEMI due to de novo disease and no restriction in vessel size. More than 80% of the culprit vessels in both groups had diameter ≥ 3mm, indicating that the great majority of patients treated had large vessel disease. The median vessel diameter was 3.5mm in both groups. Furthermore, the groups were well balanced in terms of baseline patient characteristics. The only differences were that the DCB group had more patients with previous stroke while the DES group had more patients with history of smoking. In terms of angiographic characteristics, the DCB group had more patients with bifurcations and true bifurcations treated indicating that complex disease was treated, and possibly reflects operator bias towards a DCB-only approach in bifurcations.

**Limitations**

The retrospective, non-randomised nature of our cohort from a single centre is a possible source of bias. However, our institution provides cardiac intervention as a large tertiary centre to a population in excess of 1.5 million people for pPCI, and has one of the highest implantation of DCBs for coronary artery disease in the UK (23). In addition, we included all consecutive patients fulfilling the inclusion criteria ameliorating referral bias. DCB-only angioplasty, as most interventional techniques, is accompanied by a learning curve; therefore, our results might not be generalizable to smaller institutions with less clinical experience in DCB-only strategy. Our data did not allow us to use the ARC-HBR criteria which were published a few years after the start of our cohort (24). However, we have calculated and run the analysis using the ‘Acuity’ score. Finally, even though this study is retrospective and non-randomised, our clinical database was completed prospectively and the high-rate of DCB implantation in our institution resulted in groups well-balanced in terms or patient and angiographic characteristics. Lastly, despite our efforts we were not able to review the follow up angiograms of 9 (1.9%) patients in the DCB group and 13(1.9%) patients in the DES group who have had re-PCI elsewhere.

**Conclusion**

In conclusion, this is the largest cohort analysis comparing DCB-only angioplasty to 2nd generation DES in STEMI reporting on all-cause mortality and all net adverse cardiac events including unplanned TLR. Using propensity matching, we have demonstrated that DCB-only angioplasty is safe with no difference in mortality or any of net adverse cardiac events including unplanned TLR, compared to DES in STEMI.

**Clinical perspective**

* pPCI has significantly improved the prognosis of patients with STEMI. DCB-only angioplasty for patients with STEMI has not been fully evaluated.
* In this analysis of 1139 patients with STEMI there was no difference in all-cause mortality after an average of 3 years, between DCB and 2nd generation DES. There was no difference in any of the net adverse cardiac events including unplanned TLR.
* DCB-only angioplasty in STEMI appears safe and can be considered.

**References**

1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–77. DOI 10.1093/eurheartj/ehx393PMID 28886621

2. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: Evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62(6):496–504. DOI 10.1016/j.jacc.2013.05.022PMID 23747778

3. Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(9):1061–73. DOI 10.1016/j.jacc.2019.12.046PMID 32138967

4. Merinopoulos I, Gunawardena T, Wickramarachchi U, Ryding A, Eccleshall S, Vassiliou V. Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future? Curr Cardiol Rev. 2018;14(1):45–52. DOI 10.2174/1573403X14666171226144120

5. Jeger R V., Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020;13(12):1391–402. DOI 10.1016/j.jcin.2020.02.043PMID 32473887

6. Rissanen TT, Uskela S, Eränen J, Mäntylä P, Olli A, Romppanen H, Siljander A, Pietilä M, Minkkinen MJ, Tervo J, Kärkkäinen JM, Vatanen A, Perälä A, Müller M, Porela P, Palojoki E. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. 2019;394(10194):230–9. DOI 10.1016/S0140-6736(19)31126-2PMID 31204115

7. Jeger R V, Farah A, Ohlow M, Mangner N, Möbius-winkler S, Leibundgut G, Weilenmann D. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label non-inferiority trial. Lancet. 2018;6736(18):1–8. DOI 10.1016/S0140-6736(18)31719-7

8. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. DOI 10.1093/eurheartj/ehy394PMID 30165437

9. Merinopoulos I, Gunawardena T, Corballis N, Bhalraam U, Gilbert T, Maart C, Richardson P, Ryding A, Sarev T, Sawh C, Sulfi S, Wickramarachchi U, Wistow T, Mohamed MO, Mamas MA, Vassiliou VS, Eccleshall SC. Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice. Clin Res Cardiol. 2022; DOI 10.1007/s00392-022-02106-y

10. Merinopoulos I, Gunawardena T, Wickramarachchi U, Richardson P, Maart C, Sreekumar S, Sawh C, Wistow T, Sarev T, Ryding A, Gilbert T, Perperoglou A, Vassiliou VS, Eccleshall SC. Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study. Clin Res Cardiol. 2020; DOI 10.1007/s00392-020-01734-6

11. Ho HH. Preliminary experience with drug-coated balloon angioplasty in primary percutaneous coronary intervention. World J Cardiol. 2015;7(6):311. DOI 10.4330/wjc.v7.i6.311PMID 26131335

12. Teacher L, Yellow D, King A, Zhang JC, Liu LH, Road Y. Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. J Cardiothorac Surg. 2021;16(1):1–7. DOI 10.1186/s13019-021-01525-8

13. Nijhoff F, Agostoni P, Belkacemi A, Nathoe HM, Voskuil M, Samim M, Doevendans PA, Stella PR. Primary percutaneous coronary intervention by drug-eluting balloon angioplasty: The nonrandomized fourth arm of the DEB-AMI (drug-eluting balloon in ST-segment elevation myocardial infarction) trial. Catheter Cardiovasc Interv. 2015;86:S34–44. DOI 10.1002/ccd.26060PMID 26119971

14. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, Van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW. Standardized end point definitions for coronary intervention trials: The academic research consortium-2 consensus document. Circulation. 2018;137(24):2635–50. DOI 10.1161/CIRCULATIONAHA.117.029289PMID 29891620

15. Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, Arora S, Street A, Parker S, Roberts HC, Bardsley M, Conroy S. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775–82. DOI 10.1016/S0140-6736(18)30668-8PMID 29706364

16. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian S V., Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2010;55(23):2556–66. DOI 10.1016/j.jacc.2009.09.076PMID 20513595

17. Grines C, Browse K, Marco J, Rothbaum D, Stone G, O’Keefe J, Overlie P, Donohue B, Chelliah N, Timmis G, Vlietstra R, Strzelecki M, Puchrowicz-Ochocki S, W O. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328(10):673–9. DOI 10.1056/NEJM199303113281001

18. Zijlstra F. Long-term benefit of primary angioplasty compared to thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2000;21(18):1487–9. DOI 10.1053/euhj.2000.2192PMID 10973757

19. Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F. Outcomes with various drug-eluting or bare metal stents in patients with st-segment-elevation myocardial infarction: A mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. Circ Cardiovasc Interv. 2013;6(4):378–90. DOI 10.1161/CIRCINTERVENTIONS.113.000415PMID 23922145

20. Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink MA, Oh PC, Ahn JM, Musto C, Díaz de la Llera LS, Cho YS, Violini R, Park SJ, Suryapranata H, Piek JJ, de Winter RJ, Wykrzykowska JJ, Spaulding C, Kang WC, Slagboom T, et al. Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2019;74(21):2572–84. DOI 10.1016/j.jacc.2019.09.038PMID 31753202

21. Vos NS, Fagel ND, Amoroso G, Herrman JPR, Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T, Vink MA. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial. JACC Cardiovasc Interv. 2019;12(17):1691–9. DOI 10.1016/j.jcin.2019.04.016

22. Gobić D, Tomulić V, Lulić D, Židan D, Brusich S, Jakljević T, Zaputović L. Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: A Feasibility Study. Am J Med Sci. 2017;354(6):553–60. DOI 10.1016/j.amjms.2017.07.005PMID 29208251

23. Ludman PF. BCIS Audit returns adult interventional procedures [Internet]. 2019 [cited 2019 Oct 28].

24. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632–53. DOI 10.1093/eurheartj/ehz372PMID 31116395

**Figure titles and legends**

**Figure 1. Title: Consort diagram**

**Figure 1. Legend: Consort diagram indicating how the final population included in the analysis was identified**

**STEMI: ST segment elevation myocardial infarction, DCB: drug coated balloon, DES: drug eluting stent, POBA: plain old balloon angioplasty, BMS: bare metal stent**

**Figure 2. Title: Kaplan Meier estimator plot of all-cause mortality**

**Figure 2. Legend: Kaplan Meier estimator plot of all-cause mortality for DCB vs 2nd generation DES with numbers at risk shown below the graph. DCB: drug coated balloon, DES: drug eluting stent**

**Figure 3. Title: Kaplan Meier estimator plot in propensity score matched groups**

**Figure 3. Legend: Kaplan Meier estimator plot in propensity score matched groups showing no difference in mortality between DCB and DES.**

**DCB: drug coated balloon, DES: drug eluting stent**

**Tables**

**Table 1. Baseline patient characteristics**

| **Characteristic** | **Overall**, N = 1,139*1* | **DCB**, N = 452 | **DES**, N = 687 | **p-value** |
| --- | --- | --- | --- | --- |
| Age, Mean (SD) | 66 (12) | 66 (13) | 66 (11) | 0.97*2* |
| Sex, n (%) |  |  |  | 0.69*4* |
| Male | 839 (74) | 330 (73) | 509 (74) |  |
| Female | 300 (26) | 122 (27) | 178 (26) |  |
| Hypercholesterolaemia, n (%) | 179 (16) | 79 (17) | 100 (15) | 0.18*4* |
| Hypertension, n (%) | 424 (37) | 183 (40) | 241 (35) | 0.065*4* |
| Peripheral vascular disease, n (%) | 14 (1.2) | 7 (1.5) | 7 (1.0) | 0.43*4* |
| Stroke, n (%) | 30 (2.6) | 18 (4.0) | 12 (1.7) | **0.021***4* |
| Previous myocardial infarction, n (%) | 65 (5.7) | 30 (6.6) | 35 (5.1) | 0.27*4* |
| Previous percutaneous coronary intervention, n (%) | 54 (4.7) | 25 (5.5) | 29 (4.2) | 0.31*4* |
| Previous coronary artery bypass graft, n (%) | 11 (1.0) | 5 (1.1) | 6 (0.9) | 0.76*3* |
| Heart failure, n (%) | 4 (0.4) | 2 (0.4) | 2 (0.3) | 0.65*3* |
| Atrial fibrillation, n (%) | 91 (8.0) | 37 (8.2) | 54 (7.9) | 0.84*4* |
| Family history of IHD, n (%) | 114 (10) | 44 (9.7) | 70 (10) | 0.80*4* |
| Chronic obstructive pulmonary disease, n (%) | 62 (5.4) | 27 (6.0) | 35 (5.1) | 0.52*4* |
| Diabetes, n (%) | 146 (13) | 63 (14) | 83 (12) | 0.36*4* |
| Smoking (current / previous), n (%) | 689 (63) | 254 (58) | 435 (67) | **0.006***4* |
| Estimated glomerular filtration rate, Mean (SD) | 91 (26) | 92 (27) | 90 (25) | 0.23*2* |
| Frailty Score, Median (IQR) | 0.00 (0.00 – 0.70) | 0.00 (0.00 – 0.80) | 0.00 (0.00 – 0.50) | **0.034***2* |
| Acuity score, Median (IQR) | 17 (14 – 23) | 17 (14 – 23) | 18 (14 – 23) | 0.87*2* |
| Discharge medications |  |  |  |  |
| Aspirin, n (%) | 1,100 (97.5) | 421 (94.4) | 679 (99.6) | **<0.001***4* |
| Second antiplatelet, n (%) | 1,125 (99.7) | 446 (100) | 679 (99.6) | 0.16*4* |
| DAPT duration (Mean, SD) | 347 (77) | 348 (78) | 346 (77) | 0.73*2* |
| Anticoagulation | 54 (4.8) | 23 (5.2) | 31 (4.5) | 0.64*4* |
| Beta blocker, n (%) | 1,051 (93.2) | 414 (92.8) | 637 (93.4) | 0.71*4* |
| ACE inhibitor / ARB, n (%) | 1,053 (93.4) | 415 (93.0) | 638 (93.5) | 0.74*4* |
| Statin, n (%) | 1,104 (97.9) | 437 (98.0) | 667 (97.8) | 0.84*4* |
| Aldosterone antagonist, n (%) | 155 (13.7) | 60 (13.5) | 95 (13.9) | 0.82*4* |
| *1* Median (IQR); Range; n (%); Mean (SD) | | | | |
| *2* Wilcoxon rank sum test | | | | |
| *3* Fisher's exact test | | | | |
| *4* Pearson's Chi-squared test | | | | |

**Table 1. Baseline patient characteristics of patients treated with DCB or DES. Bold characters indicate significant result.**

**DCB: drug coated balloon, DES: drug eluting stent, eGFR: estimated glomerular filtration rate**

**Table 2. Angiographic characteristics of target vessels**

| **Characteristic** | **Overall**, N = 1,139*1* | **DCB**, N = 452 | **DES**, N = 687 | **p-value** |
| --- | --- | --- | --- | --- |
| Vessel treated, n (%) |  |  |  | 0.075*3* |
| LMS | 7 (0.6) | 2 (0.4) | 5 (0.7) |  |
| LAD | 452 (40) | 196 (43) | 256 (37) |  |
| LCx | 181 (16) | 78 (17) | 103 (15) |  |
| RCA | 496 (44) | 175 (39) | 321 (47) |  |
| Graft | 3 (0.3) | 1 (0.2) | 2 (0.3) |  |
| LMS treated, n (%) | 7 (0.6) | 2 (0.4) | 5 (0.7) | 0.71*3* |
| LMS/LAD treated, n (%) | 459 (40) | 198 (44) | 261 (38) | 0.050*4* |
| Multivessel PCI, n (%) | 43 (3.8) | 17 (3.8) | 26 (3.8) | 0.98*4* |
| Bifurcation, n (%) | 386 (34) | 188 (42) | 198 (29) | **<0.001***4* |
| True bifurcation, n (%) | 88 (7.7) | 50 (11) | 38 (5.5) | **<0.001***4* |
| Heavy calcification, n (%) | 159 (14) | 67 (15) | 92 (13) | 0.50*4* |
| Vessel diameter, Median (IQR) | 3.50 (3.00 – 4.00) | 3.50 (3.00 – 3.50) | 3.50 (3.00 – 4.00) | **<0.001***2* |
| Lesion length, Median (IQR) | 25 (20 – 32) | 25 (20 – 30) | 24 (18 – 32) | 0.93*2* |
| Culprit Vessel ≥3mm, n (%) | 958 (85) | 363 (81) | 595 (87) | **0.008***4* |
| TIMI flow pre-PCI, n (%) |  |  |  | 0.28*4* |
| 0/1 | 852 (75) | 330 (73) | 522 (76) |  |
| 2/3 | 286 (25) | 121 (27) | 165 (24) |  |
| TIMI flow post-PCI, n (%) |  |  |  | 0.75*3* |
| 0/1 | 9 (0.8) | 4 (0.9) | 5 (0.7) |  |
| 2/3 | 1,130 (99) | 448 (99) | 682 (99) |  |
| Coronary Dissection, n (%) |  |  |  | >0.99*3* |
| No angiographic dissection | 317 (70) | 317 (70) | 0 (NA) |  |
| Type A | 72 (16) | 72 (16) | 0 (NA) |  |
| Type B | 62 (14) | 62 (14) | 0 (NA) |  |
| Bifurcation treatment strategy, n (%) |  |  |  | **<0.001***3* |
| DCB MB Only | 148 (38) | 148 (79) | 0 (0) |  |
| DCB SB Only | 20 (5.2) | 20 (11) | 0 (0) |  |
| DCB MB & SB | 17 (4.4) | 17 (9.1) | 0 (0) |  |
| DCB MB & POBA SB | 2 (0.5) | 2 (1.1) | 0 (0) |  |
| DES MB | 169 (44) | 0 (0) | 169 (85) |  |
| DES MB & SB | 8 (2.1) | 0 (0) | 8 (4.0) |  |
| DES MB & POBA SB | 6 (1.6) | 0 (0) | 6 (3.0) |  |
| DES SB Only | 15 (3.9) | 0 (0) | 15 (7.6) |  |
| *1* Median (IQR); Range; n (%); Mean (SD) | | | | |
| *2* Wilcoxon rank sum test | | | | |
| *3* Fisher's exact test | | | | |
| *4* Pearson's Chi-squared test | | | | |

**Table 2. Angiographic characteristics of target vessels treated with DCB or DES.**

**DCB: drug coated balloon, DES: drug eluting stent, LMS: left main stem, LAD: left anterior descending, Cx: left circumflex, RCA: right coronary artery, TIMI: thrombolysis in myocardial infarction, bold characters indicate significant result**

**Table 3. Univariable Cox regression analysis**

| **Mortality** (Univariate) | **N** | **HR** **(95% CI)***1* | **p-value** |
| --- | --- | --- | --- |
| DES |  | 0.78 (0.53 to 1.13) | 0.18 |
| Age | 1,139 | 1.09 (1.07 to 1.11) | **<0.001** |
| Female |  | 1.29 (0.87 to 1.93) | 0.21 |
| Hypercholesterolaemia | 1,139 | 0.75 (0.43 to 1.32) | 0.32 |
| Hypertension | 1,139 | 1.50 (1.03 to 2.18) | **0.033** |
| Peripheral vascular disease | 1,139 | 5.84 (2.56 to 13.3) | **<0.001** |
| Stroke | 1,139 | 3.98 (2.01 to 7.88) | **<0.001** |
| Previous Myocardial infarction | 1,139 | 2.49 (1.42 to 4.36) | **0.001** |
| PCI | 1,139 | 1.40 (0.65 to 3.01) | 0.39 |
| CABG | 1,139 | 4.95 (2.02 to 12.1) | **<0.001** |
| Heart failure | 1,139 | 31.6 (11.4 to 87.4) | **<0.001** |
| Atrial fibrillation | 1,139 | 2.46 (1.48 to 4.08) | **<0.001** |
| Family history | 1,139 | 0.37 (0.15 to 0.90) | **0.029** |
| COPD | 1,139 | 3.57 (2.13 to 5.98) | **<0.001** |
| Diabetes | 1,139 | 2.13 (1.38 to 3.31) | **<0.001** |
| Current / ex-smoker | 1,090 | 0.98 (0.66 to 1.45) | 0.90 |
| eGFR | 1,138 | 0.97 (0.96 to 0.98) | **<0.001** |
| Frailty | 1,139 | 1.24 (1.18 to 1.30) | **<0.001** |
| Acuity score | 1,102 | 1.12 (1.09 to 1.15) | **<0.001** |
| LMS treated | 1,139 | 8.88 (3.62 to 21.8) | **<0.001** |
| Multivessel PCI | 1,139 | 1.00 (0.37 to 2.73) | >0.99 |
| Vessel diameter | 1,133 | 0.93 (0.68 to 1.27) | 0.64 |
| Lesion length | 1,133 | 1.01 (0.99 to 1.02) | 0.38 |
| Vessel ≥3mm | 1,133 | 0.85 (0.52 to 1.39) | 0.52 |
| TIMI flow post-PCI | 1,139 | 0.91 (0.13 to 6.55) | 0.93 |
| Bifurcation | 1,139 | 1.39 (0.95 to 2.03) | 0.088 |
| True bifurcation | 1,139 | 2.69 (1.64 to 4.42) | **<0.001** |
| Heavy calcification | 1,135 | 2.50 (1.66 to 3.78) | **<0.001** |
| *1* HR = Hazard Ratio, CI = Confidence Interval | | | |

**Table 3. Results of univariable Cox regression analysis for all-cause mortality.**

**PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft, COPD: chronic obstructive pulmonary disease, eGFR: estimated glomerular filtration rate, TIMI: thrombolysis in myocardial infarction. Bold characters significant result**

**Table 4. Multivariable Cox regression analysis**

| All-Cause Mortality (Multivariate) | **N** | **HR** **(95% CI)***1* | **p-value** |
| --- | --- | --- | --- |
| DCB/DES [DES] | 1,138 | 0.90 (0.80 to 1.02) | 0.11 |
| Age | 1,138 | 1.01 (1.00 to 1.01) | **0.020** |
| History of Cerebrovascular Events | 1,138 | 1.36 (0.93 to 1.98) | 0.11 |
| History of Heart Failure | 1,138 | 11.6 (4.29 to 31.5) | **<0.001** |
| Family History of Coronary Artery Disease | 1,138 | 0.66 (0.53 to 0.80) | **<0.001** |
| Estimated glomerular filtration rate | 1,138 | 1.00 (1.00 to 1.00) | 0.13 |
| Frailty Score | 1,138 | 1.06 (1.02 to 1.10) | **0.001** |
| *1* HR = Hazard Ratio, CI = Confidence Interval | | | |

**Table 4. Results of multivariable Cox regression analysis**

**DCB: drug coated balloon, DES: drug eluting stent, bold characters indicate significant result**

**Table 5. Multivariable Cox regression analysis for propensity matched population**

**Table 5. Results of multivariable Cox regression analysis for propensity matched population**

| All-Cause Mortality (Multivariate) | **N** | **HR** **(95% CI)***1* | **p-value** |
| --- | --- | --- | --- |
| DCB/DES | 878 | 0.89 (0.78 to 1.01) | 0.080 |
| History of Heart Failure | 878 | 8.94 (3.28 to 24.4) | **<0.001** |
| Family History of Coronary Artery Disease | 878 | 0.68 (0.53 to 0.86) | **0.002** |
| Bifurcations | 878 | 1.14 (0.99 to 1.30) | 0.067 |
| Frailty Score | 878 | 1.06 (1.02 to 1.10) | **<0.001** |
| Acuity Score | 878 | 1.01 (1.00 to 1.02) | **0.031** |
| *1* HR = Hazard Ratio, CI = Confidence Interval | | | |


**PVD: peripheral vascular disease, COPD: chronic obstructive pulmonary disease, DES: drug eluting stent \* indicates significant result**

**Figures**


**Figure 1**



**Figure 2**

****

**Figure 3**

****

**Supplementary material**

Supplementary table 1: ICD-10 codes used to identify patients’ outcomes



|  |  |
| --- | --- |
| **Acute coronary syndrome** | |
| STEMI | I210\* I211\* I212\* I213 |
| NSTEACS | I214 I219 I200 (UA) |
| Re-infarction | I22\* |
| **Stroke** | |
| Ischaemic stroke | I63\* |
| Transient ischaemic attack | G459, G453 |
| **Major bleeding** | |
| Subarachnoid haemorrhage | I60\* |
| Intracerebral haemorrhage | I61\* |
| Non-traumatic intracranial bleeding | I62\* |
| Gastrointestinal bleeding | K920, K921, K922 |
| Haemorrhage not elsewhere specified | R58X |



Supplementary table 1: ICD-10 codes used to identify patients’ outcomes.

Supplementary figure 1: Yearly usage of DCB and DES in patients with first STEMI presentation due to de novo disease fulfilling inclusion criteria



Supplemental figure 2: Kaplan Meier for net adverse cardiac events in full cohort







Supplement figure 3: Kaplan Meier plots for net adverse cardiac events in matched cohort

